IDEAYA Biosciences IDYA 深 滬
等待開盤 09-10 09:30:00 美东时间
24.74
+1.350
+5.77%
華盛通- 最 高25.09
- 今 開24.06
- 成交量 216.00万股
- 最 低 23.5255
- 昨 收 23.39
- 總市值 21.68亿
- 52周最高 36.64
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 13.45
- 委 比 -33.09%
- 總股本 8764.37万
- 歷史最高 47.735
- 量 比 1.08
- 振 幅 6.69%
- 歷史最低 2.95
- 每 手 1
- 風險率 4.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Stock markets have lost their oomph, no longer a leading economic indicator
Factors such as fewer initial public offerings and passive investing have led to a situation where there is "no alpha" left in stock markets, according to an Apollo economist. Meanwhile, a former JPMo...
今天 00:29
Cantor Fitzgerald Reiterates Overweight on IDEAYA Biosciencesto Overweight
Cantor Fitzgerald analyst Li Watsek reiterates IDEAYA Biosciences (NASDAQ:IDYA) from Overweight to Overweight.
09-09 21:15
Stephens & Co. Reiterates Overweight on IDEAYA Biosciences, Maintains $45 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Overweight and maintains $45 price target.
09-09 21:11
中邮证券-恒瑞医药-600276-2025年半年报点评：对外许可常态化，员工持股计划明确创新药产出规划-250909
（来源：研报虎） 事件 公司发布2025年半年报，上半年实现营业收入157.6亿元(+15.9%)、归母净利润44.5亿元(+29.7%)、扣非归母净利润...
09-09 15:16
SA analyst upgrades/downgrades: TSLA, NVDA, MDB, and MAR
MongoDB (NASDAQ:MDB) received a significant upgrade following impressive Q2 earnings that delivered a 49% EPS surprise, suggesting the company is successfully positioning itself as a leader in AI appl...
09-09 00:56
Biggest stock movers Monday: RAPP, HOUR, IDYA, NFE and more
U.S. stock futures edged up on Monday as investors looked ahead to two important inflation reports this week, that will shape expectations for the Federal Reserve's next move. Here are some of Monday'...
09-08 17:15
“创新药一哥”BD凶猛！恒瑞医药心肌病新药NewCo出海，总交易额超10亿美元
本文来源：时代财经 作者：张羽岐 图片来源：图虫创意 “创新药一哥”再拿下一笔出海交易。9月5日，恒瑞医药（600276.SH；01276.HK）对外宣布...
09-05 22:55
IDEAYA Biosciences (IDYA) Has a New Rating from Barclays
In a report released today, Peter Lawson from Barclays initiated coverage with ...
09-04 15:47
Market-Moving News for September 2nd
ONC: 9% | BeOne Medicines shares are trading higher after the company last week announced topline results from a Phase 1/2 study of sonrotoclax in adult patients with relapsed/refractory mantle cell lymphoma,
09-02 19:23
